+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904660
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antiviral Drugs Market has witnessed substantial growth from USD 59.84 billion in 2024 to USD 63.81 billion in 2025. This upward trajectory is projected to continue with a CAGR of 6.57%, enabling the market to reach USD 87.67 billion by 2030.

Reframing Antiviral Therapeutics for the Modern Era

The antiviral therapeutics sector is at a crucial turning point, fueled by groundbreaking scientific advancements and pressing global health demands. As viral threats increase in complexity and scope, stakeholders in research, manufacturing, and clinical care need strategic recalibrations to stay effective. Through an exploration of emerging molecular mechanisms and evolving policy landscapes, this comprehensive analysis emphasizes the need for an agile, insight-driven approach to navigating these challenges.

Incorporating precision medicine with traditional antiviral strategies has opened innovative avenues for targeting viral replication and host immune responses. Collaborations between academic institutions, biotech companies, and pharmaceuticals have accelerated both discovery and commercialization. This introductory section highlights transformative market dynamics, regulatory shifts, and competitive positioning—providing a panoramic view of the current opportunities and obstacles.

Integrating recent scientific breakthroughs with macroeconomic insights, this section offers decision-makers a lucid perspective on the existing ecosystem, emphasizing the significance of cohesive partnerships across the value chain and identifying critical vantage points for antiviral drug development.

Emerging Breakthroughs Reshaping the Antiviral Arena

The antiviral market is undergoing a transformational change, spurred by advances in genomic technologies, novel drug classes, and changing patient care models. Precision-guided therapies are on the cusp of redefining standard care across various viral indications, aided by the integration of real-world data and artificial intelligence that enhances clinical trial design and post-market monitoring.

The rise of biosimilars and combination regimens has sharpened competitive dynamics, prompting established firms to reconsider pricing strategies. Regulatory agencies are adapting pathways that balance accelerated approvals with safety evaluations, demanding robust health-economic evidence. This conjuncture of innovation, regulatory flexibility, and payer scrutiny is revolutionizing antiviral drug discovery, development, and delivery.

To harness these shifts, stakeholders must adopt flexible models and foster multidisciplinary alliances, necessitating strategic foresight and operational excellence, which this section investigates thoroughly.

Navigating the Impact of US Tariffs on Antiviral Supply Chains

The implementation of revised tariff measures by the United States in early 2025 has affected the import of essential raw materials and antiviral formulations. While these tariffs aim to support domestic manufacturing, they introduce complexities in global supply chains, influencing input costs, production timelines, and pricing negotiations with healthcare entities.

Manufacturers are considering localizing crucial parts of the supply chain, requiring significant investment and regulatory navigation. At the same time, leveraging regional partnerships and trade agreements are strategies employed to mitigate tariff impacts. This shifting landscape emphasizes the importance of supply chain resilience and diversification.

Key Takeaways from This Report

  • The antiviral market is poised for significant growth, creating a strategic landscape ripe for innovation and collaboration.
  • Stakeholders benefit from insights into precision medicine integration and strategic frameworks vital for maintaining competitive advantage.
  • Understanding tariff implications can guide companies in optimizing supply chain strategies and mitigating production and distribution challenges.
  • Regional differences and market segmentation provide a foundation for developing effective market entry and expansion strategies.

Synthesis of Insights for Next Generation Antiviral Strategies

This report elucidates the antiviral market's dynamic landscape shaped by scientific innovation, policy changes, and global health priorities. It highlights the interconnected roles of transformative drug classes, new reimbursement paradigms, and strategic geographic considerations. By dissecting tariff impacts, segmentation drivers, and regional nuances, this analysis provides actionable intelligence for market decision-makers.

Top industry players leverage diverse tactics to expedite development and secure market presence. The recommendations outlined here serve as a roadmap for harnessing technological advancements, fortifying supply chains, and aligning offerings with varying user needs. These strategies ensure positioning for stakeholders to deliver next-gen antivirals effectively and sustainably.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antiviral Drugs Market, by Indication
8.1. Introduction
8.2. Hepatitis B
8.3. Hepatitis C
8.4. Herpes Simplex
8.5. Hiv
8.6. Influenza
8.7. Respiratory Syncytial Virus
9. Antiviral Drugs Market, by Drug Class
9.1. Introduction
9.2. Fusion Inhibitors
9.3. Integrase Inhibitors
9.4. Non Nucleoside Reverse Transcriptase Inhibitors
9.5. Nucleoside Analogues
9.6. Protease Inhibitors
10. Antiviral Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Inhalation
10.3. Injectable
10.4. Oral
10.5. Topical
11. Antiviral Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Clinics
11.3. Hospital Pharmacies
11.4. Online Pharmacies
11.5. Retail Pharmacies
12. Antiviral Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
12.5. Long Term Care Facilities
13. Americas Antiviral Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Antiviral Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Antiviral Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Gilead Sciences, Inc.
16.3.2. AbbVie Inc.
16.3.3. F. Hoffmann-La Roche Ltd
16.3.4. Merck & Co., Inc.
16.3.5. GlaxoSmithKline plc
16.3.6. Pfizer Inc.
16.3.7. Johnson & Johnson
16.3.8. Bristol-Myers Squibb Company
16.3.9. ViiV Healthcare Limited
16.3.10. AstraZeneca plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTIVIRAL DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTIVIRAL DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIVIRAL DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 183. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 214. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 244. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Antiviral Drugs market report include:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • ViiV Healthcare Limited
  • AstraZeneca plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 63.81 Billion
Forecasted Market Value ( USD ) by 2030 $ 87.67 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antiviral Therapeutics Market by Disease Type, Drug Class, Route Of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030 - Product Image

Antiviral Therapeutics Market by Disease Type, Drug Class, Route Of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Infectious Disease Therapeutics Market by Drug Class, Route of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Infectious Disease Therapeutics Market by Drug Class, Route of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030 - Product Image

Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030

  • Report
  • 296 Pages
  • Global
From
Antiviral Combination Therapy Market Report 2025 - Product Image

Antiviral Combination Therapy Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Antivirals Market

The Antivirals market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat viral infections. Antivirals are used to treat a wide range of viral infections, including influenza, HIV, herpes, hepatitis, and other respiratory infections. Antivirals work by targeting the virus itself, preventing it from replicating and spreading throughout the body. They can also be used to reduce the severity of symptoms and shorten the duration of the illness. Antivirals are typically administered orally or intravenously, depending on the type of virus and the severity of the infection. In some cases, antivirals may be used in combination with other drugs to increase their effectiveness. Some of the major companies in the Antivirals market include Gilead Sciences, Merck & Co., Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb. These companies produce a variety of antiviral drugs, including those used to treat influenza, HIV, herpes, and hepatitis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.